Report Feature
The future of the global biopharmaceutical contract manufacturing market looks promising with opportunities in commercial and clinical applications. The global biopharmaceutical contract manufacturing market is expected to grow with a CAGR of 7%-9% from 2020 to 2025. The major drivers for this market are increasing demand for biopharmaceuticals, cost and time saving benefits offered by contract services, and rising pharmaceutical industries leading to outsourcing services.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biopharmaceutical contract manufacturing market report, please download the report brochure.
In this market, biologics is the largest product of biopharmaceutical contract manufacturing, whereas process development is the largest service. Growth in various segments of the biopharmaceutical contract manufacturing market are given below:
The study includes trends and forecast for the global biopharmaceutical contract manufacturing market by product, service, therapeutic area, source, application, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Biologics
- Monoclonal Antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi (Ribonucleic Acid), & Molecular Therapy
- Biosimilars
By Service [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC (Quality Control) Studies
- Packaging
By Therapeutic Area [Value ($ Million) shipment analysis for 2014 – 2025]:
- Autoimmune Disease
- Oncology
- Metabolic Disease
- Ophthalmology
- Cardiovascular Disease
- Infectious Disease
- Neurology
- Respiratory Disorder
- Others
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
- Mammalian
- Non-Mammalian
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
- Commercial
- Clinical
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- France
-
Asia Pacific
- China
- India
- Japan
-
The Rest of the World
- Brazil
Some of the biopharmaceutical contract manufacturing companies profiled in this report include Lonza, Inno Biologics, Rentschler Biotechnologie, JRS Pharma, AGC Biologics, ProBioGen, Fujifilm Diosynth Biotechnologies, Toyobo, Samsung BioLogics, and Thermo Fisher Scientific.
Lucintel forecasts that biologics will remain the largest product segment over the forecast period due to increasing stringent regulatory framework related to biologics which is forcing pharmaceutical companies to adopt for contract manufacturing services.
Within this market, process development will remain the largest service segment over the forecast period due to the presence of advanced technologies and high capital expenditure in small and medium pharmaceutical companies that are opting for contract manufacturing.
North America will remain the largest region over the forecast period due to increasing research activities related to biopharmaceutical, rising demand for biologics, and presence of major pharmaceutical companies in the region.
|
Features of the Global Biopharmaceutical Contract Manufacturing Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global biopharmaceutical contract manufacturing market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, and vaccines), antisense, RNAi, & molecular therapy, and biosimilars), service (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging), therapeutic area (autoimmune disease, oncology, metabolic disease, ophthalmology, cardiovascular disease, infectious disease, neurology, respiratory disorder, and others), source (mammalian and non-mammalian), application (commercial and clinical), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biopharmaceutical contract manufacturing market? Q.5 What are the business risks and threats to the global biopharmaceutical contract manufacturing market? Q.6 What are the emerging trends in this biopharmaceutical contract manufacturing market and the reasons behind them? Q.7 What are some changing demands of customers in this biopharmaceutical contract manufacturing market? Q.8 What are the new developments in this biopharmaceutical contract manufacturing market? Which companies are leading these developments? Q.9 Who are the major players in this biopharmaceutical contract manufacturing market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this biopharmaceutical contract manufacturing market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global biopharmaceutical contract manufacturing market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Product (Biologics, Antisense, RNAi, & Molecular Therapy, and Biosimilars), Service (Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging), Therapeutic Area (Autoimmune Disease, Oncology, Metabolic Disease, Ophthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others), Source (Mammalian and Non-Mammalian), and Application (Commercial and Clinical) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Biopharmaceutical Contract Manufacturing Market
4.1 Global Biopharmaceutical Contract Manufacturing Market by Region
4.2.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.2.2 Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.2.3 Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.2.4 Market by Source: Mammalian and Non-Mammalian
4.2.5 Market by Application: Commercial and Clinical
4.2.6 The United States Biopharmaceutical Contract Manufacturing Market
4.2.7 The Canadian Biopharmaceutical Contract Manufacturing Market
4.2.8 The Mexican Biopharmaceutical Contract Manufacturing Market
4.3.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.3.2 Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.3.3 Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.3.4 Market by Source: Mammalian and Non-Mammalian
4.3.5 Market by Application: Commercial and Clinical
4.3.6 The Biopharmaceutical Contract Manufacturing Market of United Kingdom
4.3.7 The German Biopharmaceutical Contract Manufacturing Market
4.3.8 The French Biopharmaceutical Contract Manufacturing Market
4.4.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.4.2 Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.4.3 Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.4.4 Market by Source: Mammalian and Non-Mammalian
4.4.5 Market by Application: Commercial and Clinical
4.4.6 The Chinese Biopharmaceutical Contract Manufacturing Market
4.4.7 The Indian Biopharmaceutical Contract Manufacturing Market
4.4.8 The Japanese Biopharmaceutical Contract Manufacturing Market
4.5.1 Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.5.2 Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.5.3 Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.5.4 Market by Source: Mammalian and Non-Mammalian
4.5.5 Market by Application: Commercial and Clinical
4.5.6 Brazilian Biopharmaceutical Contract Manufacturing Market
7.1.1 Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Product
7.1.2 Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Service
7.1.3 Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
7.1.4 Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Source
7.1.5 Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Application
7.1.6 Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
